We are monitoring the impact of COVID-19 on MEA Melanoma Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 797
Share on
Share on

Middle East & Africa Melanoma Therapeutics Market Research Report - Segmented By Cancer Stage, Cancer Type, Diagnosis, Treatment & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 797
Pages: 145

MEA Melanoma Therapeutics Market Size (2021 to 2026)

The Middle East and Africa Melanoma Therapeutics Market was worth USD 0.18 billion in 2021 and estimated to be growing at a CAGR of 13.49%, to reach USD 0.34 billion by 2026. The melanoma market in the Middle East and Africa has seen an unmatched boost in market size due to the dynamically developing nature of melanoma treatments over the recent past.

Even though many treatment choices are available today, various immunotherapies and combination therapies are anticipated to arrive on the market. Large-scale acceptance of these new treatments is expected due to their enhanced survival benefits and minor side effects.

Melanoma can develop in areas heavily exposed to the sun, such as the back, legs, arms, and other regions. The growing population in the region is driving the demand for melanoma therapeutics in the market. Melanoma can develop in areas heavily exposed to the sun, such as the back, legs, arms, and other regions. Also, the technological advancements for developing new and innovative therapies and increasing demand for better treatment and effective therapies propel the market growth. 

In addition, the increasing initiatives for developing proper medical and health care infrastructure in the region also contribute to the market's growth. Furthermore, the increased investments from government and private organizations in research activities for developing effective therapies and drugs for treating melanoma in the region, rising awareness among the people about the programs for pre- diagnosing of melanoma, and treatments available in the market help in increasing the growth of the MEA melanoma therapeutics market.

However, an increase in the high costs of the treatment and therapies with the lack of poor reimbursements policies are majorly restraining the growth of the melanoma therapeutics market. In addition, the lack of awareness about melanoma among people and the presence of treatment and therapies available in the market are limiting the market's growth.

Further, the strict government rules and regulations and stringent approval policies make the entry of the product difficult and hamper the market's growth. In addition, the lack of availability of appropriate treatment facilities and well-developed healthcare services impeded the development of the melanoma therapeutics market.

This research report on the MEA melanoma therapeutics market has been segmented and sub-segmented into the following categories:

By Cancer Stage:

  • Stage 0
  • Stage I
  • Stage II
  • Stage III
  • Stage IV

By Cancer Type:

  • Nodular Melanoma
  • Acral Lentiginous Melanoma
  • Superficial Spreading Melanoma
  • Lentigno Maligna Melanoma
  • Amelanotic Melanoma
  • Others

By Diagnosis:

  • Ultrasound
  • Blood Tests
  • Dermatoscopy
  • Sentinel Lymph Node Biopsy
  • X-rays
  • CT Scan

By Treatment:

  • Early Melanoma
  • Advanced Melanoma-Biological Therapy
  • Targeted Therapy
  • Surgery
  • Chemotherapy
  • Radiotherapy 
  • Immune Therapy

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

The Middle East and Africa are estimated to register a moderate share in the global market during the forecast period. In recent years, the shifting focus of key market players from developed to developing markets is enabling market growth in the region. Also, the increasing melanoma cases and skin allergies due to the sunny weather, depleting health diet, and health habits are expected to help in boosting the market growth in the melanoma market. Moreover, rapidly expanding economies and their attraction towards significant market players are looking to expand their facilities in these countries. In addition, the recent increase in melanoma cases and specific skin allergies is also increasing the demand in the region.

South Africa held the largest share of the MEA melanoma therapeutics market in 2020, and it is likely to continue its dominance throughout the forecast period. Improving the healthcare sector, government initiatives to promote research and development activities for developing effective drugs and medication also contribute to the growth of melanoma therapeutics.

UAE is expected to register an exponential growth rate during the forecast period due to the growing healthcare spending, increasing government initiatives for attracting major market players to invest their resources in the region, and favorable reimbursement policies. Another factor for the growth of the market is the increasing melanoma cases in UAE.

KEY MARKET PLAYERS:

A few of the key players operating in the MEA melanoma therapeutics market profiled in this report are Bristol-Myers Squibb Co., Merck and Co., F. Hoffmann-La Roche, Amgen Inc., Celgene Corp, Daiichi Sankyo, and Pfizer Inc.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By cancer stage                      

                             5.1.1 Stage 0     

                             5.1.2 Stage I      

                             5.1.3 Stage II     

                             5.1.4 Stage III   

                             5.1.5 Stage IV   

              5.2 By cancer type                        

                             5.2.1 Nodular melanoma           

                             5.2.2 Acral lentiginous melanoma          

                             5.2.3 Superficial spreading melanoma  

                             5.2.4 Lentigno maligna melanoma         

                             5.2.5 Amelanotic melanoma     

                             5.2.6 Others     

              5.3 By Diagnosis                           

                             5.3.1 Ultrasound            

                             5.3.2 Blood Tests           

                             5.3.3 Dermatoscopy      

                             5.3.4 Sentinel lymph node biopsy           

                             5.3.5 X-rays       

                             5.3.6 CT Scan    

              5.4 By Treatment                         

                             5.4.1 Early melanoma   

                             5.4.2 Advanced melanoma        

                                           5.4.2.1 Biological therapy

                                           5.4.2.2 Targeted therapy

                                           5.4.2.3 Surgery

                                           5.4.2.4 Chemotherapy

                                           5.4.2.5 Radiotherapy

                                           5.4.2.6 Immune therapy

6. Geographical Analysis                                         

              6.1 Introduction                           

              6.2 Middle-East                            

              6.3 Africa                         

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 Bristol-Myers Squibb Co                     

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 Merck and Co                         

              9.3 F. Hoffmann-La Roche                        

              9.4 Amgen Inc                

              9.5 Celgene Corp                          

              9.6 Daiichi Sankyo                        

              9.7 Pfizer Inc                   

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East & Africa Melanoma Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  2. Middle East & Africa Melanoma Therapeutics Market By Cancer stage , From 2021 to 2026 (USD Billion)
  3. Middle East & Africa Stage 0 Market By Region, From 2021 to 2026 (USD Billion)
  4. Middle East & Africa Stage I Market By Region, From 2021 to 2026 (USD Billion)
  5. Middle East & Africa Stage II Market By Region, From 2021 to 2026 (USD Billion)
  6. Middle East & Africa Stage III Market By Region, From 2021 to 2026 (USD Billion)
  7. Middle East & Africa Stage IV Market By Region, From 2021 to 2026 (USD Billion)
  8. Middle East & Africa Melanoma Therapeutics Market By Cancer type , From 2021 to 2026 (USD Billion)
  9. Middle East & Africa Nodular melanoma Market By Region, From 2021 to 2026 (USD Billion)
  10. Middle East & Africa Acral lentiginous melanoma Market By Region, From 2021 to 2026 (USD Billion)
  11. Middle East & Africa Superficial spreading melanoma Market By Region, From 2021 to 2026 (USD Billion)
  12. Middle East & Africa Lentigno maligna melanoma Market By Region, From 2021 to 2026 (USD Billion)
  13. Middle East & Africa Amelanotic melanoma Market By Region, From 2021 to 2026 (USD Billion)
  14. Middle East & Africa Other cancers Market By Region, From 2021 to 2026 (USD Billion)
  15. Middle East & Africa Melanoma Therapeutics Market By Diagnosis, From 2021 to 2026 (USD Billion)
  16. Middle East & Africa Ultrasound Market By Region, From 2021 to 2026 (USD Billion)
  17. Middle East & Africa Blood Tests Market By Region, From 2021 to 2026 (USD Billion)
  18. Middle East & Africa Dermatoscopy Market By Region, From 2021 to 2026 (USD Billion)
  19. Middle East & Africa Sentinel lymph node biopsy Market By Region, From 2021 to 2026 (USD Billion)
  20. Middle East & Africa X-rays Market By Region, From 2021 to 2026 (USD Billion)
  21. Middle East & Africa CT Scan Market By Region, From 2021 to 2026 (USD Billion)
  22. Middle East & Africa Melanoma Therapeutics Market By Treatment, From 2021 to 2026 (USD Billion)
  23. Middle East & Africa early melanoma Market By Region, From 2021 to 2026 (USD Billion)
  24. Middle East & Africa advanced melanoma Market By Region, From 2021 to 2026 (USD Billion)
  25. Middle East & Africa Melanoma Therapeutics Market By Advanced Melanoma, From 2021 to 2026 (USD Billion)
  26. Middle East & Africa Biological therapy Market By Region, From 2021 to 2026 (USD Billion)
  27. Middle East & Africa Targeted therapy Market By Region, From 2021 to 2026 (USD Billion)
  28. Middle East & Africa Surgery Market By Region, From 2021 to 2026 (USD Billion)
  29. Middle East & Africa Chemotherapy Market By Region, From 2021 to 2026 (USD Billion)
  30. Middle East & Africa Radiotherapy Market By Region, From 2021 to 2026 (USD Billion)
  31. Middle East & Africa Immune therapy Market By Region, From 2021 to 2026 (USD Billion)
  32. Middle East Melanoma Therapeutics Market By Cancer stage , From 2021 to 2026 (USD Billion)
  33. Middle East Melanoma Therapeutics Market By Cancer type , From 2021 to 2026 (USD Billion)
  34. Middle East Melanoma Therapeutics Market By Diagnosis, From 2021 to 2026 (USD Billion)
  35. Middle East Melanoma Therapeutics Market By Treatment, From 2021 to 2026 (USD Billion)
  36. Middle East Melanoma Therapeutics Market By Advanced Melanoma, From 2021 to 2026 (USD Billion)
  37. Africa Melanoma Therapeutics Market By Cancer stage , From 2021 to 2026 (USD Billion)
  38. Africa Melanoma Therapeutics Market By Cancer type , From 2021 to 2026 (USD Billion)
  39. Africa Melanoma Therapeutics Market By Diagnosis, From 2021 to 2026 (USD Billion)
  40. Africa Melanoma Therapeutics Market By Treatment, From 2021 to 2026 (USD Billion)
  41. Africa Melanoma Therapeutics Market By Advanced Melanoma, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample